scholarly journals Allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning in primary refractory prolymphocytic leukemia: graft-versus-leukemia effect without graft-versus-host disease

2001 ◽  
Vol 28 (12) ◽  
pp. 1155-1156 ◽  
Author(s):  
L Castagna ◽  
A Nozza ◽  
A Bertuzzi ◽  
L Siracusano ◽  
I Timofeeva ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Peripheral Blood Stem Cell ◽  
Reduced Intensity Conditioning ◽  
Prolymphocytic Leukemia ◽  
Graft Versus Host ◽  
Graft Versus Leukemia ◽  
Blood Stem Cell Transplantation ◽  
Reduced Intensity ◽  
Graft Versus Leukemia Effect

Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes

Blood ◽  
2002 ◽  
Vol 100 (6) ◽  
pp. 2243-2245 ◽  
Author(s):  
Rodrigo Martino ◽  
Marı́a Dolores Caballero ◽  
José Antonio Pérez Simón ◽  
Carmen Canals ◽  
Carlos Solano ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Reduced Intensity Conditioning ◽  
Graft Versus Leukemia ◽  
Blood Stem Cell Transplantation ◽  
Reduced Intensity ◽  
Graft Versus Leukemia Effect

Abstract We report the results of a prospective study of a reduced-intensity conditioning (RIC) regimen followed by allogeneic peripheral blood stem cell transplantation (PBSCT) from an HLA-identical sibling in 37 patients with acute myeloid leukemia (AML; n = 17) or myelodysplastic syndrome (MDS; n = 20). The median age was 57 years, and 22 (59%) were beyond the early phase of their disease. The incidence of grade II to IV acute graft-versus-host disease (GVHD) was 19% (5% grade III-IV), and the 1-year incidence of chronic extensive GVHD was 46%. With a median follow-up of 297 days (355 days in 24 survivors), the 1-year probability of transplant-related mortality was 5%, and the 1-year progression-free survival was 66%. The 1-year incidence of disease progression in patients with and without GVHD was 13% (95% CI, 4%-34%) and 58% (95% CI, 36%-96%), respectively (P = .008). These results suggest that a graft-versus-leukemia effect plays a crucial role in reducing the risk of relapse after a RIC allograft in AML and MDS.

Sign in / Sign up

Export Citation Format

Share Document